They demonstrated an effective treatment by using the promoter of CCKAR, suggesting the feasibility of pancreatic-cancer-specific promoter-based gene therapy in pancreatic cancer treatment. This evidence concerns the gene CCKAR and familial pancreatic carcinoma.